FIELD: biotechnology.
SUBSTANCE: peptidomimetic macrocycle is proposed that binds to the Growth-Hormone-Releasing Hormone (GHRH) receptor and its use. The peptidomimetic macrocycle proposed has a structure as shown in the formula.
EFFECT: peptidomimetic macrocycle has improved biological activity, stimulates the production and release of growth hormone and can be used to increase lean muscle mass in the patient, to reduce adipose tissue in the patient, to treat muscle atrophy, lipodystrophy, growth hormone, gastric paresis, or short-term syndrome guts in a patient.
31 cl, 11 dwg, 5 tbl, 4 ex
| Title | Year | Author | Number |
|---|---|---|---|
| p53 PEPTIDOMIMETIC MACROCYCLES | 2013 |
|
RU2642299C2 |
| PEPTIDOMIMETIC MACROCYCLES | 2011 |
|
RU2582678C2 |
| GLUCAGON SUPERFAMILY PEPTIDES EXHIBITING NUCLEAR HORMONE RECEPTOR ACTIVITY | 2011 |
|
RU2604067C2 |
| PEPTIDES WITH AFFINITY FOR PARATHYROID HORMONE AND ACTIVITY- STIMULATING ADENYLCYCLASES | 1996 |
|
RU2157699C2 |
| INSULIN-INCRETIN CONJUGATES | 2014 |
|
RU2678134C2 |
| PEPTIDE PRO-DRUGS OF AMIDE GLUCAGON SUPERFAMILY | 2011 |
|
RU2580317C2 |
| IL-15 CONJUGATES AND THEIR USES | 2019 |
|
RU2793754C2 |
| INTERLEUKIN 10 CONJUGATES AND OPTIONS FOR THEIR USE | 2019 |
|
RU2815891C2 |
| PEGILATED BIOLOGICALLY ACTIVE PEPTIDES AND THEIR APPLICATION | 2017 |
|
RU2748576C2 |
| CYTOKINE CONJUGATES FOR TREATMENT OF AUTOIMMUNE DISEASES | 2018 |
|
RU2787201C2 |
